Positive Results from MT-302 In Vivo CAR Therapy
CREATE Medicines Inc., a clinical-stage biotechnology company, has recently reported encouraging first-in-human results for its innovative treatment, MT-302, which targets advanced solid tumors. The findings were presented at a prominent meeting of cancer immunotherapy experts.
Advancements in In Vivo CAR Therapy
The Phase 1 MYE Symphony trial evaluated the safety and efficacy of MT-302, focusing on how this mRNA-LNP-encoded therapy can manipulate immune cells to combat solid tumors. As researchers explore the tumor microenvironment, they have discovered promising evidence supporting the effectiveness of in vivo programmed myeloid cells.
Insights from the Trial
Rasha Cosman BSc (Med), MBBS, FRACP, played a key role in analyzing the data. She emphasized how the results show significant remodeling in the immune system. Notably, there was a manageable safety profile and signs of anti-tumor activity. The trial showcased how immune cells can be reprogrammed within the body, which represents a pivotal point for future treatments aimed at solid tumors.
Key Findings
The study involved 27 participants with advanced solid tumors, specifically those expressing TROP2. Noteworthy findings included:
- A manageable safety profile consistent with expected immune cell activation.
- Low-grade cytokine release syndrome was observed in nearly 52% of participants, which aligns with their tumor engagement.
- The highest tolerated dose was determined to be 0.10 mg/kg, demonstrating feasibility for repeat dosing.
- MT-302 showed biological activity as CAR+ myeloid cells were found in tumors with T-cell involvement.
- Crucially, one patient with HR+ breast cancer experienced a confirmed partial response after 16 months of treatment.
Scientific and Clinical Implications
Dr. Matt Maurer, Chief Medical Officer of CREATE Medicines, notes that the study is groundbreaking, marking the first time an in vivo CAR therapy has shown significant immune cell activity and tumor infiltration in patients. This trial not only demonstrates proof of the therapy's mechanism but also highlights its potential for future applications.
Future Directions for MT-302
The success of MT-302 in the current study has underlined its role as a strong candidate for first-line therapy. Additionally, an upcoming trial will investigate the use of MT-302 combined with standard frontline treatment, which could offer significant benefits for patients.
A Transformative Moment for In Vivo Cell Therapy
Daniel Getts PhD, co-founder and CEO of CREATE Medicines, reflected on the implications of the findings: this represents a transformative opportunity for cell therapy. The ability to leverage the body's immune system to target tumors opens up a vast realm of possibilities in cancer treatment.
Details of the Scientific Presentation
As the scientific community contemplates the implications of these findings, the presentation at the Society for Immunotherapy of Cancer's Annual Meeting delivered detailed insights into the safety and efficacy of MT-302:
- Title: First-in-Human Dose Escalation Study of mRNA-LNP MT-302 In Vivo CAR Therapy
- Presenting Author: Dr. Rasha Cosman
About MT-302 and CREATE Medicines
MT-302 stands out as an investigational mRNA-LNP therapy specifically designed to train the immune system to fight TROP2-positive tumors, eliminating the need for complex ex vivo manipulation. CREATE Medicines, previously known as Myeloid Therapeutics, is pioneering advancements in multi-immune programming with a commitment to delivering scalable treatments for various health conditions, including cancer and autoimmune diseases.
Frequently Asked Questions
What is MT-302?
MT-302 is an investigational therapy utilizing mRNA-LNP technology designed to reprogram immune cells to target TROP2-positive tumors.
What were the results of the trial?
The trial reported a manageable safety profile and biological activity, including a confirmed partial response in a patient after 16 months of treatment.
Who conducted the study?
The study was conducted by CREATE Medicines, a biotechnology company focused on advancing in vivo cell programming therapies.
What does this mean for cancer treatment?
The study's positive outcomes suggest new possibilities for in vivo therapies in treating solid tumors, potentially offering more effective treatments for patients.
When will MT-302 be further tested?
Further testing of MT-302 in a combination with standard frontline therapy is planned to build on the successful results of the initial trial.
